1,546 Shares in DaVita Inc. (NYSE:DVA) Purchased by Farringdon Capital Ltd.

Farringdon Capital Ltd. bought a new stake in shares of DaVita Inc. (NYSE:DVA) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 1,546 shares of the company’s stock, valued at approximately $231,000.

Other institutional investors have also recently made changes to their positions in the company. Invesco Ltd. raised its position in shares of DaVita by 20.9% in the fourth quarter. Invesco Ltd. now owns 1,589,545 shares of the company’s stock valued at $237,716,000 after buying an additional 275,284 shares during the last quarter. Amundi boosted its holdings in shares of DaVita by 116.4% during the 4th quarter. Amundi now owns 446,386 shares of the company’s stock worth $68,726,000 after purchasing an additional 240,126 shares during the last quarter. Bridgewater Associates LP increased its holdings in shares of DaVita by 298.4% in the fourth quarter. Bridgewater Associates LP now owns 239,970 shares of the company’s stock valued at $35,888,000 after purchasing an additional 179,744 shares during the last quarter. Skandinaviska Enskilda Banken AB publ boosted its stake in DaVita by 256.8% during the fourth quarter. Skandinaviska Enskilda Banken AB publ now owns 162,233 shares of the company’s stock worth $24,301,000 after buying an additional 116,758 shares during the last quarter. Finally, JPMorgan Chase & Co. increased its stake in shares of DaVita by 17.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 609,076 shares of the company’s stock worth $99,846,000 after acquiring an additional 92,014 shares during the last quarter. 90.12% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

DVA has been the topic of a number of analyst reports. Barclays lifted their target price on shares of DaVita from $164.00 to $169.00 and gave the stock an “equal weight” rating in a research note on Tuesday, February 18th. Cowen reissued a “hold” rating on shares of DaVita in a research note on Tuesday, February 18th. Sanford C. Bernstein set a $184.00 price target on DaVita in a research note on Friday, February 21st. Finally, StockNews.com raised DaVita from a “hold” rating to a “buy” rating in a research report on Thursday, April 10th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $166.33.

DaVita Stock Performance

Shares of DaVita stock opened at $140.21 on Friday. The company has a debt-to-equity ratio of 23.18, a current ratio of 1.26 and a quick ratio of 1.21. The stock has a market capitalization of $11.22 billion, a price-to-earnings ratio of 13.05, a price-to-earnings-growth ratio of 1.07 and a beta of 1.04. The business has a 50-day moving average of $149.13 and a 200 day moving average of $156.00. DaVita Inc. has a 12 month low of $128.69 and a 12 month high of $179.60.

DaVita (NYSE:DVA) last announced its quarterly earnings data on Thursday, February 13th. The company reported $2.24 earnings per share for the quarter, beating analysts’ consensus estimates of $2.14 by $0.10. DaVita had a net margin of 7.31% and a return on equity of 115.48%. As a group, sell-side analysts forecast that DaVita Inc. will post 10.76 earnings per share for the current year.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.